Friday, May 24, 2013

Rivaroxaban approved for ACS secondary prevention in Europe

The European Commission has approved a 2.5-mg twice-daily dosage based on the ATLAS ACS 2 TIMI 51 trial.

via The Heart

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)